Pathos AI announced a USD 237 million Series E on 23 October 2026, led by Bristol Myers Squibb. The New York company develops an artificial intelligence platform for oncology drug discovery and development. Its Foundry system combines clinical data, genomics, biological samples and competitive intelligence to guide portfolio and trial decisions. Existing investors also participated. Pathos will use the financing to expand the platform and advance its oncology pipeline, including the JSKN016 antibody drug conjugate. The new capital is separate from the approximately USD 3 billion post money valuation reported alongside the transaction.
Pathos AI raises USD 237 million for oncology drug development
Bristol Myers Squibb leads the Series E.

Keep reading
More Funding

BrightAI secures USD 97 million to scale physical AI infrastructure
Smith Point Capital led the investment in sensor based monitoring for essential services.

Dcubed raises EUR 27.2 million to expand space hardware production
Warsaw Equity Group led the oversubscribed Series A plus round for the German manufacturer.

Linq raises USD 90 million to expand AI powered mobile infrastructure
Andreessen Horowitz led the Series B and partner Ben Horowitz joined the board.


